What Researchers Did
Researchers presented a case report detailing a patient with cutaneous B-cell lymphoma who experienced rapid disease progression during hyperbaric oxygen therapy.
What They Found
They found that a patient with cutaneous B-cell lymphoma and non-healing ulcerations, who began hyperbaric oxygen (HBO₂) therapy, experienced worsening wounds shortly after treatment initiation. Subsequent biopsies confirmed rapid progression to cutaneous large B-cell lymphoma, leading to HBO₂ discontinuation and aggressive chemotherapy.
What This Means for Canadian Patients
Canadian patients with a history of cutaneous B-cell lymphoma who are considering or undergoing hyperbaric oxygen therapy should be closely monitored for any signs of tumor recurrence or disease worsening. Early detection of such changes is crucial to promptly adjust treatment strategies and prevent rapid disease progression.
Canadian Relevance
This specific case report has no direct Canadian connection.
Study Limitations
As a single case report, these findings may not be generalizable to all patients with cutaneous B-cell lymphoma undergoing hyperbaric oxygen therapy.